S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)

LAVA Therapeutics (LVTX) News Today

$2.12
+0.05 (+2.42%)
(As of 02/26/2024 ET)
SourceHeadline
benzinga.com logoLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest Report
benzinga.com - February 21 at 4:27 PM
investing.com logoLAVA Therapeutics NV (LVTX)
investing.com - February 14 at 3:12 PM
msn.com logoLava signs collaboration agreement with MSD for prostate cancer therapy
msn.com - January 25 at 8:11 PM
seekingalpha.com logoPCSA, ONCO and KAVL among mid-day movers
seekingalpha.com - January 25 at 3:11 PM
finance.yahoo.com logoLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
finance.yahoo.com - January 25 at 10:11 AM
ca.finance.yahoo.com logoLAVA Therapeutics N.V. (LVTX)
ca.finance.yahoo.com - December 13 at 8:17 AM
morningstar.com logoLAVA Therapeutics NV LVTX
morningstar.com - November 11 at 10:20 AM
bizjournals.com logoLava Therapeutics is latest life sciences company to trim its workforce
bizjournals.com - August 25 at 3:39 PM
finanznachrichten.de logoLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
finanznachrichten.de - August 22 at 9:28 AM
finance.yahoo.com logoLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
finance.yahoo.com - August 22 at 9:28 AM
msn.com logoLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34
msn.com - July 6 at 8:59 PM
finanznachrichten.de logoLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
finanznachrichten.de - June 14 at 1:02 PM
msn.com logoLava Therapeutics shelves hematology drug over competitive concerns
msn.com - June 14 at 1:02 PM
msn.com logoHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy Recommendation
msn.com - June 12 at 5:49 PM
markets.businessinsider.com logoJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)
markets.businessinsider.com - June 9 at 1:23 AM
finance.yahoo.com logoLAVA Therapeutics to Participate in the Jefferies Healthcare Conference
finance.yahoo.com - June 1 at 10:23 AM
finance.yahoo.com logoLAVA Announces Annual Meeting of Shareholders
finance.yahoo.com - May 30 at 8:35 PM
uk.finance.yahoo.com logoIs a Beat Likely for Cooper Companies (COO) in Q2 Earnings?
uk.finance.yahoo.com - May 30 at 10:34 AM
benzinga.com logoLAVA Therapeutics Stock (NASDAQ:LVTX), Dividends
benzinga.com - April 17 at 6:23 PM
markets.businessinsider.com logoJMP Securities Sticks to Its Buy Rating for LAVA Therapeutics (LVTX)
markets.businessinsider.com - April 12 at 2:35 AM
finance.yahoo.com logoLAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
finance.yahoo.com - April 11 at 9:54 AM
finance.yahoo.com logoLAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
finance.yahoo.com - March 9 at 8:55 AM
finance.yahoo.com logoLAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
finance.yahoo.com - February 16 at 9:45 AM
finance.yahoo.com logoLAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
finance.yahoo.com - February 9 at 7:58 AM
markets.businessinsider.com logoLAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical Officer
markets.businessinsider.com - February 6 at 10:57 AM
marketbeat.com logoLAVA Therapeutics (NASDAQ:LVTX) Sees Significant Drop in Short Interest
marketbeat.com - January 27 at 10:12 PM
seekingalpha.com logoLVTX LAVA Therapeutics N.V.
seekingalpha.com - January 26 at 3:23 PM
finance.yahoo.com logoLAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
finance.yahoo.com - January 23 at 8:59 AM
finance.yahoo.com logoLAVA Therapeutics Announces Appointment of New Directors to the Board
finance.yahoo.com - January 6 at 1:40 PM
finance.yahoo.com logoLAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 7:11 AM
finance.yahoo.com logoLAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
finance.yahoo.com - December 10 at 4:14 PM
finance.yahoo.com logoWill LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - November 14 at 1:23 PM
finance.yahoo.com logoLAVA Therapeutics to Present at the Jefferies London Healthcare Conference
finance.yahoo.com - November 4 at 3:33 PM
finance.yahoo.com logoLAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
finance.yahoo.com - November 3 at 1:20 PM
finance.yahoo.com logoLAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
finance.yahoo.com - November 1 at 8:00 AM
seekingalpha.com logoLAVA Therapeutics: Assessing A Promising Innovator
seekingalpha.com - October 18 at 3:10 AM
finance.yahoo.com logoLAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
finance.yahoo.com - October 7 at 3:12 PM
markets.businessinsider.com logoAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), LAVA Therapeutics (LVTX) and Design Therapeutics (DSGN)
markets.businessinsider.com - September 28 at 7:14 AM
za.investing.com logo5 Analyst Price Target Changes of Note
za.investing.com - September 26 at 7:51 PM
finance.yahoo.com logoLAVA Therapeutics Skyrockets After Cancer Agreement With Seagen
finance.yahoo.com - September 26 at 2:50 PM
markets.businessinsider.com logoSeagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223
markets.businessinsider.com - September 26 at 9:41 AM
finance.yahoo.com logoSeagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
finance.yahoo.com - September 26 at 9:41 AM
nasdaq.com logoLAVA Therapeutics N.V. (LVTX) Upgraded to Buy: Here's What You Should Know
nasdaq.com - September 16 at 4:37 PM
finanznachrichten.de logoLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results
finanznachrichten.de - September 14 at 7:48 AM
finance.yahoo.com logoLAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 7 at 8:27 AM
benzinga.com logoLAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program
benzinga.com - June 17 at 7:52 AM
finance.yahoo.com logoLAVA Therapeutics Announces Two Appointments to its Board of Directors
finance.yahoo.com - June 15 at 7:21 AM
finance.yahoo.com logoLAVA Therapeutics to Participate at the Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 8:27 AM
finance.yahoo.com logoLAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 1 at 9:47 AM
finance.yahoo.com logoWhy LAVA Therapeutics (LVTX) Might Surprise This Earnings Season
finance.yahoo.com - May 16 at 4:16 PM
Get LAVA Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter.



LVTX Media Mentions By Week

LVTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LVTX
News Sentiment

0.92

0.45

Average
Medical
News Sentiment

LVTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LVTX Articles
This Week

1

0

LVTX Articles
Average Week

Get LAVA Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:LVTX) was last updated on 2/26/2024 by MarketBeat.com Staff